VIVUS Company Profile (NASDAQ:VVUS)

About VIVUS (NASDAQ:VVUS)

VIVUS logoVIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:VVUS
  • CUSIP: 92855110
  • Web: www.vivus.com
Capitalization:
  • Market Cap: $84.13 million
  • Outstanding Shares: 105,812,000
Average Prices:
  • 50 Day Moving Avg: $0.94
  • 200 Day Moving Avg: $1.07
  • 52 Week Range: $0.78 - $1.47
P/E:
  • Trailing P/E Ratio: 2.6639
  • Foreward P/E Ratio: -1.77
  • P/E Growth: -2.7300
Sales & Book Value:
  • Annual Revenue: $133.4 million
  • Price / Sales: 0.63
  • Book Value: $0.05 per share
  • Price / Book: 15.29
Profitability:
  • EBITDA: $67.14 million
  • Net Margins: 24.72%
  • Return on Equity: 3,746.48%
  • Return on Assets: 11.02%
Debt:
  • Debt-to-Equity Ratio: 40.25%
  • Current Ratio: 5.51%
  • Quick Ratio: 5.20%
Misc:
  • Average Volume: 799,803 shs.
  • Beta: 0.96
  • Short Ratio: 9.72
 

Frequently Asked Questions for VIVUS (NASDAQ:VVUS)

What is VIVUS's stock symbol?

VIVUS trades on the NASDAQ under the ticker symbol "VVUS."

How were VIVUS's earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) posted its quarterly earnings results on Thursday, August, 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.31) by $0.20. The company had revenue of $13.77 million for the quarter, compared to analysts' expectations of $19 million. VIVUS had a return on equity of 3,746.48% and a net margin of 24.72%. The firm's revenue was down 40.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.19) earnings per share. View VIVUS's Earnings History.

When will VIVUS make its next earnings announcement?

VIVUS is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for VIVUS.

Who are some of VIVUS's key competitors?

Who are VIVUS's key executives?

VIVUS's management team includes the folowing people:

  • David York Norton, Chairman of the Board and Director
  • Seth H. Z. Fischer, Chief Executive Officer, Chief Commercial Officer, Director
  • Mark K. Oki CPA, Chief Financial Officer, Chief Accounting Officer
  • John L. Slebir Esq., Senior Vice President - Business Development, General Counsel, Secretary
  • Guy P. Marsh, Vice President - U.S. Operations, General Manager
  • Johann Noor Mohamed, Vice President, Corporate Controller
  • Wesley W. Day Ph.D., Vice President - Clinical Development
  • Santosh T. Varghese M.D, Vice President-Medical & Regulatory Affairs, Pharmacovigilance, and QA
  • Thomas B. King, Director
  • Herman Rosenman CPA, Director

How do I buy VIVUS stock?

Shares of VIVUS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VIVUS's stock price today?

One share of VIVUS stock can currently be purchased for approximately $0.80.


MarketBeat Community Rating for VIVUS (NASDAQ VVUS)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  488
MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for VIVUS (NASDAQ:VVUS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for VIVUS (NASDAQ:VVUS)
Price Target History for VIVUS (NASDAQ:VVUS)
Analysts' Ratings History for VIVUS (NASDAQ:VVUS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/25/2016WallachBeth CapitalSet Price TargetBuy$2.80N/AView Rating Details
5/4/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
3/10/2016Needham & Company LLCReiterated RatingHoldN/AView Rating Details
2/29/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$4.00 -> $1.00N/AView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for VIVUS (NASDAQ:VVUS)
Earnings by Quarter for VIVUS (NASDAQ:VVUS)
Earnings History by Quarter for VIVUS (NASDAQ VVUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.13)N/AView Earnings Details
5/3/2017Q1 2017($0.13)($0.01)$27.01 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.23$0.54$48.82 million$81.81 millionViewListenView Earnings Details
11/9/2016Q316($0.19)($0.09)$21.91 million$13.40 millionViewListenView Earnings Details
8/4/2016Q216($0.31)($0.11)$19.00 million$13.77 millionViewN/AView Earnings Details
5/3/2016Q116($0.21)($0.12)$17.97 million$15.32 millionViewN/AView Earnings Details
3/9/2016Q4($0.12)($0.12)$22.90 million$15.34 millionViewN/AView Earnings Details
11/4/2015Q315($0.17)($0.15)$20.24 million$24.90 millionViewN/AView Earnings Details
7/30/2015Q215($0.23)($0.19)$18.76 million$23.00 millionViewListenView Earnings Details
5/5/2015Q115($0.22)($0.15)$21.80 million$32.20 millionViewN/AView Earnings Details
2/24/2015Q414($0.25)($0.25)$20.00 million$21.70 millionViewListenView Earnings Details
11/5/2014Q314($0.25)($0.10)$21.90 million$33.90 millionViewListenView Earnings Details
8/7/2014Q214($0.28)($0.25)$17.90 million$21.90 millionViewListenView Earnings Details
5/5/2014Q114($0.37)($0.15)$11.40 million$36.70 millionViewN/AView Earnings Details
2/24/2014Q413($0.40)($0.17)$28.20 million$44.06 millionViewListenView Earnings Details
11/5/2013Q313($0.38)($0.48)$21.78 million$27.38 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.44)($0.55)$12.76 million$5.53 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.51)($0.53)$5.22 million$4.10 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.44)($0.56)$3.09 million$1.97 millionViewN/AView Earnings Details
11/6/2012Q312($0.34)($0.40)$0.35 million$0.04 millionViewN/AView Earnings Details
8/7/2012($0.23)($0.24)ViewN/AView Earnings Details
5/7/2012($0.13)($0.20)ViewN/AView Earnings Details
2/28/2012($0.12)($0.14)ViewN/AView Earnings Details
11/7/2011($0.12)($0.10)ViewN/AView Earnings Details
8/1/2011($0.13)($0.20)ViewN/AView Earnings Details
5/2/2011($0.15)($0.12)ViewN/AView Earnings Details
2/28/2011($0.22)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for VIVUS (NASDAQ:VVUS)
Current Year EPS Consensus Estimate: $-0.3900 EPS
Next Year EPS Consensus Estimate: $-0.4500 EPS

Dividends

Dividend History for VIVUS (NASDAQ:VVUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for VIVUS (NASDAQ:VVUS)
Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 35.73%
Insider Trades by Quarter for VIVUS (NASDAQ:VVUS)
Institutional Ownership by Quarter for VIVUS (NASDAQ:VVUS)
Insider Trades by Quarter for VIVUS (NASDAQ:VVUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2017Santosh T VargheseInsiderSell434$0.97$420.98View SEC Filing  
7/3/2017Santosh T VargheseInsiderSell423$1.23$520.29View SEC Filing  
4/4/2017Santosh T VargheseInsiderSell440$1.08$475.20View SEC Filing  
3/10/2017North Tide Capital, LlcMajor ShareholderSell1,149,400$1.16$1,333,304.00View SEC Filing  
3/7/2017North Tide Capital, LlcMajor ShareholderSell192,800$1.08$208,224.00View SEC Filing  
3/2/2017North Tide Capital, LlcMajor ShareholderSell160,100$1.13$180,913.00View SEC Filing  
2/27/2017North Tide Capital, LlcMajor ShareholderSell333,000$1.14$379,620.00View SEC Filing  
2/22/2017North Tide Capital, LlcMajor ShareholderSell161,800$1.11$179,598.00View SEC Filing  
2/16/2017North Tide Capital, LlcMajor ShareholderSell305,090$1.10$335,599.00View SEC Filing  
2/13/2017North Tide Capital, LlcMajor ShareholderSell176,410$1.11$195,815.10View SEC Filing  
2/8/2017North Tide Capital, LlcMajor ShareholderSell563,527$1.06$597,338.62View SEC Filing  
2/7/2017North Tide Capital, LlcMajor ShareholderSell6,200$1.11$6,882.00View SEC Filing  
2/6/2017North Tide Capital, LlcMajor ShareholderSell28,027$1.10$30,829.70View SEC Filing  
2/3/2017North Tide Capital, LlcMajor ShareholderSell78,633$1.12$88,068.96View SEC Filing  
1/28/2017Santosh T VargheseInsiderSell429$1.11$476.19View SEC Filing  
12/31/2016Santosh T VargheseInsiderSell13,790$1.12$15,444.80View SEC Filing  
10/1/2016Santosh T VargheseInsiderSell710$1.14$809.40View SEC Filing  
8/2/2016Santosh T VargheseInsiderSell12,559$1.07$13,438.13View SEC Filing  
7/1/2016Santosh T VargheseVPSell366$1.21$442.86View SEC Filing  
4/7/2016Santosh T VargheseInsiderSell329$1.65$542.85View SEC Filing  
4/1/2016North Tide Capital, LlcMajor ShareholderBuy2,160$1.40$3,024.00View SEC Filing  
3/31/2016North Tide Capital, LlcMajor ShareholderBuy383,300$1.29$494,457.00View SEC Filing  
3/28/2016North Tide Capital, LlcMajor ShareholderBuy202,000$1.12$226,240.00View SEC Filing  
3/16/2016North Tide Capital, LlcMajor ShareholderBuy500,000$1.21$605,000.00View SEC Filing  
1/1/2016John L SlebirSVPSell2,973$3.04$9,037.92View SEC Filing  
1/8/2015North Tide Capital, LlcMajor ShareholderBuy500,000$3.12$1,560,000.00View SEC Filing  
1/6/2015North Tide Capital, LlcMajor ShareholderBuy476,800$3.04$1,449,472.00View SEC Filing  
1/2/2015North Tide Capital, LlcMajor ShareholderBuy523,200$2.90$1,517,280.00View SEC Filing  
3/11/2014Seth H.Z. FischerCEOBuy3,080$6.07$18,695.60View SEC Filing  
11/11/2013Alexander DennerDirectorBuy566,844$8.59$4,869,189.96View SEC Filing  
9/5/2013Timothy E MorrisCFOSell10,654$11.95$127,315.30View SEC Filing  
9/4/2013Michael J AstrueDirectorBuy10,000$11.96$119,600.00View SEC Filing  
6/27/2013Jon C BiroInsiderBuy2,000$12.85$25,700.00View SEC Filing  
5/29/2013Ernest MarioDirectorBuy15,000$14.68$220,200.00View SEC Filing  
8/20/2012Ernest MarioDirectorBuy5,000$20.75$103,750.00View SEC Filing  
8/10/2012Ernest MarioDirectorBuy20,000$21.74$434,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for VIVUS (NASDAQ:VVUS)
Latest Headlines for VIVUS (NASDAQ:VVUS)
Source:
DateHeadline
americanbankingnews.com logoFinancial Review: VIVUS (VVUS) vs. The Competition
www.americanbankingnews.com - October 17 at 8:26 AM
americanbankingnews.com logoVIVUS (VVUS) and Sinovac Biotech (SVA) Head to Head Review
www.americanbankingnews.com - October 12 at 10:32 PM
finance.yahoo.com logoETFs with exposure to VIVUS, Inc. : October 9, 2017
finance.yahoo.com - October 10 at 8:14 AM
americanbankingnews.com logoCritical Contrast: VIVUS (VVUS) versus Its Peers
www.americanbankingnews.com - October 9 at 6:28 PM
finance.yahoo.com logoVIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 12:42 PM
americanbankingnews.com logoArgos Therapeutics (ARGS) & VIVUS (VVUS) Head-To-Head Survey
www.americanbankingnews.com - September 29 at 12:34 PM
zacks.com logoOrexigen's (OREX) Contrave Sales Improving on Promotions
www.zacks.com - September 28 at 10:20 AM
americanbankingnews.com logoCritical Survey: VIVUS (VVUS) versus Its Rivals
www.americanbankingnews.com - September 18 at 2:26 AM
americanbankingnews.com logoVIVUS, Inc. (VVUS) Sees Large Drop in Short Interest
www.americanbankingnews.com - September 15 at 1:28 AM
streetinsider.com logoVIVUS (VVUS) Says Tacrolimus Received Orphan Drug Designation in the European Union for the Treatment of PAH
www.streetinsider.com - September 8 at 10:10 AM
finance.yahoo.com logoVIVUS, Aggressive Marketing For Approved Drugs, Milestone for Tacrolimus, Pipeline Analysis
finance.yahoo.com - September 8 at 10:10 AM
finance.yahoo.com logoVIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension
finance.yahoo.com - September 7 at 11:05 AM
streetinsider.com logoVIVUS (VVUS), Alvogen Announce Marketing Agreement for Qsymia in Republic of Korea - StreetInsider.com
www.streetinsider.com - September 6 at 10:09 AM
finance.yahoo.com logoVIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea
finance.yahoo.com - September 6 at 10:09 AM
finance.yahoo.com logoVIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound?
finance.yahoo.com - September 4 at 3:41 PM
americanbankingnews.com logoVIVUS (VVUS) and Alimera Sciences (ALIM) Head to Head Survey
www.americanbankingnews.com - September 2 at 10:24 PM
americanbankingnews.com logoVIVUS, Inc. (VVUS) Expected to Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - September 2 at 2:26 AM
streetinsider.com logoVIVUS (VVUS) Settles with Dr. Reddy's Laboratories on Qsymia ... - StreetInsider.com
www.streetinsider.com - August 31 at 1:57 AM
finance.yahoo.com logoVIVUS Announces Settlement with Dr. Reddy's Laboratories on Qsymia(R) Patent Litigation
finance.yahoo.com - August 30 at 8:54 PM
seekingalpha.com logoVivid Potential Victory With Vivus, Inc. Convertible Bonds - Seeking Alpha
seekingalpha.com - August 23 at 1:46 PM
finance.yahoo.com logoVIVUS to Present at 2017 Wells Fargo Healthcare Conference on September 7, 2017
finance.yahoo.com - August 23 at 1:46 PM
americanbankingnews.com logoCritical Review: VIVUS (VVUS) & Tokai Pharmaceuticals (NVUS)
www.americanbankingnews.com - August 19 at 8:44 AM
finance.yahoo.com logoVivus Pipeline Review, Analysis and Potential Catalysts
finance.yahoo.com - August 10 at 9:34 AM
nasdaq.com logoVIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y - Nasdaq
www.nasdaq.com - August 9 at 8:59 AM
finance.yahoo.com logoVIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y
finance.yahoo.com - August 8 at 8:15 AM
americanbankingnews.com logoPeregrine Pharmaceuticals (PPHM) & VIVUS (VVUS) Head-To-Head Analysis
www.americanbankingnews.com - August 5 at 8:36 PM
feeds.benzinga.com logoVIVUS Reports Second Quarter 2017 Financial Results
feeds.benzinga.com - August 3 at 4:34 PM
americanbankingnews.com logo-$0.13 EPS Expected for VIVUS, Inc. (NASDAQ:VVUS) This Quarter
www.americanbankingnews.com - July 27 at 11:17 AM
americanbankingnews.com logoVIVUS, Inc. (NASDAQ:VVUS) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:48 AM
finance.yahoo.com logoVIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation
finance.yahoo.com - July 6 at 5:16 PM
americanbankingnews.com logoVIVUS, Inc. (NASDAQ:VVUS) Expected to Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - July 3 at 10:14 AM
streetinsider.com logoVIVUS (VVUS) Names Thomas King to Board of Directors - StreetInsider.com
www.streetinsider.com - May 26 at 8:31 AM
investorplace.com logo5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio - Investorplace.com
investorplace.com - May 26 at 8:31 AM
investorplace.com logo5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio
investorplace.com - May 25 at 7:48 AM
seekingalpha.com logoVivus' (VVUS) CEO Seth Fischer on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 11:55 PM
feeds.benzinga.com logoVIVUS Announces Date of 2017 First Quarter Business Update and Financial Results Teleconference
feeds.benzinga.com - April 25 at 8:19 AM
nasdaq.com logoVIVUS (VVUS) Down 14.1% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - April 10 at 8:24 AM
marketwatch.com logoVivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi - MarketWatch
www.marketwatch.com - March 28 at 8:19 AM
finanznachrichten.de logoVIVUS In Deal To Reacquire STENDRA Commercial Rights From Sanofi
www.finanznachrichten.de - March 27 at 7:53 PM
nasdaq.com logoVIVUS In Deal To Reacquire STENDRA Commercial Rights From Sanofi - Quick Facts
www.nasdaq.com - March 27 at 7:53 PM
us.rd.yahoo.com logoVIVUS, Inc. Reacquires STENDRA(R) (Avanafil) Commercial Rights from Sanofi
us.rd.yahoo.com - March 27 at 7:53 PM
us.rd.yahoo.com logo8:32 am Vivus reaches an agreement w/ Sanofi (SNY) for Sanofi to return the commercial rights for STENDRA in Africa, the Middle East, Turkey and Russia to the co; terms not disclosed
us.rd.yahoo.com - March 27 at 7:53 PM
biz.yahoo.com logoVIVUS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Sta
us.rd.yahoo.com - March 27 at 7:53 PM
capitalcube.com logoVIVUS, Inc. :VVUS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017
us.rd.yahoo.com - March 16 at 6:43 AM
benzinga.com logoMid-Morning Market Update: Markets Edge Higher; Staples Earnings Miss Views
www.benzinga.com - March 10 at 12:21 AM
us.rd.yahoo.com logoEdited Transcript of VVUS earnings conference call or presentation 8-Mar-17 9:30pm GMT
us.rd.yahoo.com - March 10 at 12:21 AM
seekingalpha.com logoVivus' (VVUS) CEO Seth Fischer on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 9 at 4:32 AM
biz.yahoo.com logoVIVUS INC Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 9 at 4:32 AM
us.rd.yahoo.com logoVIVUS Reports Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 9 at 4:32 AM
biz.yahoo.com logoVIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - March 9 at 4:32 AM

Social

Chart

VIVUS (VVUS) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.